2023
Serial Assessment of Coronary Artery Healing of a Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months by Optical Coherence Tomography (OCT)-The REPAIR Trial.
Silva G, Meneguz-Moreno R, Costa R, Chamié D, Dangas G, Manica A, Arruda J, Sousa A, Feres F, Costa J. Serial Assessment of Coronary Artery Healing of a Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months by Optical Coherence Tomography (OCT)-The REPAIR Trial. Journal Of Invasive Cardiology 2023, 35: e225-e233. PMID: 36920890, DOI: 10.25270/jic/22.00349.Peer-Reviewed Original ResearchConceptsOptical coherence tomographyDrug-eluting stentsCoherence tomographyStrut coverageSerial optical coherence tomographyEarly strut coverageImaging follow-upSingle-arm studyAcute coronary syndromeLocal drug toxicityPercutaneous coronary interventionType 2 diabetesFirst-generation drug-eluting stentsOpen-labelOCT assessmentBiodegradable polymer drug-eluting stentsDrug toxicityCoronary syndromeFollow-upMean agePolymer drug-eluting stentsCoronary interventionStentHealing patternPatients
2015
Bioabsorbable polymer‐coated sirolimus‐eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub‐study
Rusinaru D, Vrolix M, Verheye S, Chowdhary S, Schoors D, Di Mario C, Desmet W, Donohoe DJ, Ormiston JA, Knape C, Bezerra H, Lansky A, Wijns W, Investigators O. Bioabsorbable polymer‐coated sirolimus‐eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub‐study. Catheterization And Cardiovascular Interventions 2015, 86: 1141-1150. PMID: 25044635, DOI: 10.1002/ccd.25610.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAgedCardiac Pacing, ArtificialCardiovascular AgentsCoronary AngiographyCoronary Artery DiseaseCoronary VesselsDrug-Eluting StentsEuropeFemaleHistorically Controlled StudyHumansMaleMiddle AgedNew ZealandPercutaneous Coronary InterventionPolymersProspective StudiesSingle-Blind MethodSirolimusTime FactorsTreatment OutcomeVasoconstrictionVasodilationConceptsZotarolimus-eluting stentsDrug-eluting stentsCoronary vasomotionII trialVasomotor dysfunctionFirst-generation drug-eluting stentsEndeavor zotarolimus-eluting stentsGeneration drug-eluting stentsCoronary vasomotor dysfunctionSirolimus-eluting stentsQuantitative coronary angiographyVessel diameterMaximal pacingCoronary angiographyZES groupCoronary arteryVasomotor responsesHistorical groupStent edgeNormal vasomotionPatientsPercent changeReference segmentsVasomotionSES groupVascular response after implantation of biolimus A9-eluting stent with bioabsorbable polymer and everolimus-eluting stents with durable polymer. Results of the optical coherence tomography analysis of the BIOACTIVE randomized trial
Chamié D, Almeida B, Grandi F, Filho E, Costa J, Costa R, Staico R, Siqueira D, Feres F, Tanajura L, Centemero M, Chaves Á, Abizaid A, Sousa A, Abizaid A. Vascular response after implantation of biolimus A9-eluting stent with bioabsorbable polymer and everolimus-eluting stents with durable polymer. Results of the optical coherence tomography analysis of the BIOACTIVE randomized trial. Journal Of Transcatheter Interventions 2015, 23: 28-37. DOI: 10.1016/j.rbciev.2015.02.001.Peer-Reviewed Original ResearchOptical coherence tomography analysisVascular responsesEverolimus-eluting stentBiolimus A9-eluting stentRandomized to treatmentNeointimal hyperplasia areaIn-stent obstructionFirst-generation drug-eluting stentsFrequency of framesDrug-eluting stentsTomography analysisInflammatory infiltrateRandomized trialsPrimary outcomeNeointimal formationStentNeointimal thicknessBioabsorbable polymersHyperplasia areaStent areaStrutsPatientsMonths post-interventionStent strutsPolymer
2014
First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients
Navarese EP, Kowalewski M, Kandzari D, Lansky A, Górny B, Kołtowski Ł, Waksman R, Berti S, Musumeci G, Limbruno U, van der Schaaf RJ, Kelm M, Kubica J, Suryapranata H. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. Open Heart 2014, 1: e000064. PMID: 25332803, PMCID: PMC4189321, DOI: 10.1136/openhrt-2014-000064.Peer-Reviewed Original ResearchSecond-generation drug-eluting stentsPaclitaxel-eluting stentsDrug-eluting stentsSecond-generation EESCoronary artery diseaseMyocardial infarctionEnd pointArtery diseaseClinical trialsPrespecified safety end pointsStable coronary artery diseaseIncidence of MIFirst-generation drug-eluting stentsFirst-generation SESReduction of oddsEfficacy end pointSafety end pointTarget lesion revascularisationAcute coronary syndromeComposite end pointSafe drug-eluting stentCurrent clinical practiceLong-term safetyVessel revascularisationCardiac mortality
2012
Mid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doing.
Saito S, Nakamura S, Fujii K, Nakamura M, Isshiki T, Hirayama H, Kikuchi T, Fujita H, Nonogi H, Mitsudo K, Kimura T, Igarashi K, Saito K, Lansky AJ, Stone GW, Honda Y, Waseda K, Fitzgerald PJ, Sudhir K. Mid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doing. Journal Of Invasive Cardiology 2012, 24: 444-50. PMID: 22954564.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsDrug-eluting stentsSegment late lossJapan RegistryLate lossUS patientsEES groupPrimary endpointSingle-arm multicenter studySecond-generation drug-eluting stentsFirst-generation drug-eluting stentsLower late lossTarget vessel failureAdverse cardiac eventsMid-term resultsCardiac eventsPES groupMulticenter studyJapanese patientsNeointimal volumeApposition ratePatientsStudy aimClinical programsSerial greyscale and radiofrequency intravascular ultrasound assessment of plaque modification and vessel geometry at proximal and distal edges of bare metal and first-generation drug-eluting stents.
Ribamar Costa J, Abizaid A, Sousa A, Siqueira D, Chamié D, Feres F, Costa R, Staico R, Maldonado G, Centemero M, Tanajura L, Viana R, Chaves Á, Abizaid A, Sousa J. Serial greyscale and radiofrequency intravascular ultrasound assessment of plaque modification and vessel geometry at proximal and distal edges of bare metal and first-generation drug-eluting stents. EuroIntervention 2012, 8: 225-34. PMID: 22717925, DOI: 10.4244/eijv8i2a36.Peer-Reviewed Original ResearchConceptsVessel geometryGreyscale intravascular ultrasoundDrug-eluting stentsBare metalIntravascular ultrasoundPlaque areaPlaque compositionPatients treated with drug-eluting stentsPercentage of fibrotic tissueVH-IVUSMeasurements of vesselsDistal edgePlaque growthFirst-generation drug-eluting stentsPrimary endpointBare metal stentsFollow-up proceduresPost-procedureSingle-centreVirtual histology intravascular ultrasoundPositive vessel remodelingFibro-fatty componentFollow-upFirst report of a novel abluminal groove filled biodegradable polymer rapamycin-eluting stent in de novo coronary artery disease: results of the first in man FIREHAWK trial.
Qian J, Xu B, Lansky AJ, Yang YJ, Qiao SB, Wu YJ, Chen J, Hu FH, Yang WX, Mintz GS, Leon MB, Gao RL. First report of a novel abluminal groove filled biodegradable polymer rapamycin-eluting stent in de novo coronary artery disease: results of the first in man FIREHAWK trial. Chinese Medical Journal 2012, 125: 970-6. PMID: 22613516.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsQuantitative coronary angiographyDrug-eluting stentsAbluminal grooveMyocardial infarctionDe novo coronary artery diseaseDe novo native coronary stenosisIschemia-driven target lesion revascularizationNovo coronary artery diseaseStent late lumen lossFirst-generation drug-eluting stentsComplete strut coverageAdverse cardiac eventsTarget lesion revascularizationTarget vessel revascularizationClinical success rateCoronary artery diseaseLate lumen lossNative coronary stenosisPrior myocardial infarctionStent late lossLate DES thrombosisLong-term restenosisLesion revascularizationPrimary endpoint
2011
Comparação randomizada entre o stent eluidor de paclitaxel de nova geração sem polímero e o stent eluidor de paclitaxel com polímero durável em pacientes com doença arterial coronária: resultados da análise angiográfica e ultrassonográfica seriada do estudo PAX-A
Chamié D, Costa J, Abizaid A, Costa R, Feres F, Staico R, Siqueira D, Tanajura L, Abizaid A, Sousa A, Sousa J. Comparação randomizada entre o stent eluidor de paclitaxel de nova geração sem polímero e o stent eluidor de paclitaxel com polímero durável em pacientes com doença arterial coronária: resultados da análise angiográfica e ultrassonográfica seriada do estudo PAX-A. Journal Of Transcatheter Interventions 2011, 19: 379-391. DOI: 10.1590/s2179-83972011000400008.Peer-Reviewed Original ResearchIn-stent late luminal lossPaclitaxel-eluting stentsLate luminal lossFollow-upIn-stentEnd pointsObstruction volumeLuminal lossIntravascular ultrasoundSecondary end pointsPrimary end pointSingle-center studyAdverse cardiac eventsLocal vascular inflammationLong-term safetyNon-fatal MIFirst-generation drug-eluting stentsIncreased rates of late stent thrombosisRates of late stent thrombosisAngiographic characteristicsDrug-eluting stentsCardiac eventsMACE rateBinary restenosisVascular inflammation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply